Side Effects•Reviewed April 2026•8 min read

The side effects that most often shape the first weeks on GLP-1 therapy

Most people who struggle early are dealing with the same cluster: nausea, constipation, diarrhea, stomach discomfort, bloating, and fatigue that can disrupt eating and hydration.

This page is for general education only. It is not medical advice and should not replace care from your licensed healthcare provider.
Research note: Grounded in official Wegovy safety materials and semaglutide trial summaries. Educational only, not a substitute for clinician advice.

The official Wegovy safety materials list nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue among the most common side effects. That pattern lines up with the semaglutide trial literature, where gastrointestinal symptoms show up most often and are usually most noticeable during the dose-escalation part of treatment.

What makes these effects so disruptive is not only that they feel unpleasant. They can make it harder to eat enough protein, drink enough fluid, work normally, sleep well, and keep up with routines that help treatment feel sustainable.

Key point
GI symptoms are the most common early friction point.
Key point
Dose increases are when many people notice symptoms most.
Key point
Persistent vomiting, worsening abdominal pain, or dehydration are not symptoms to just “push through.”

What tends to show up first

The early symptom pattern is usually gastrointestinal. Official Wegovy safety information names nausea, diarrhea, vomiting, constipation, stomach pain, bloating, belching, reflux-type discomfort, and fatigue among the more common side effects. In practice, many users describe the first problem less as one dramatic event and more as a steady sense that food and routine suddenly feel harder.

That matters because the side effects do not stay isolated to the stomach. A person who feels nauseated often drinks less, eats less, and becomes less active. That can make the whole week feel more fragile than the medication discussion alone would suggest.

Why dose changes often feel harder

The semaglutide GI tolerability literature and the STEP obesity program both support the idea that these symptoms are often most noticeable around dose escalation. Many events are described as mild to moderate and temporary, but temporary does not mean trivial. A few rough days can still be enough to disrupt hydration, intake, and confidence.

This is one reason side-effect tracking is useful. A person may feel as if the medication “suddenly stopped fitting,” when the more accurate explanation is that a dose increase created a short but meaningful strain on the body.

Why fatigue often shows up alongside GI symptoms

Fatigue is listed in official Wegovy side-effect materials, but it often makes more sense when viewed together with intake and hydration. When a person is eating less, drinking less, sleeping poorly, or feeling ongoing nausea, tiredness is not random. It is often part of the same pattern.

That does not mean every case of fatigue is harmless. It means fatigue is more useful when interpreted alongside symptoms, food intake, fluids, bowel changes, and recovery rather than as a standalone complaint.

When a side effect becomes a medical question

Official safety information is clear that nausea, vomiting, or diarrhea that does not go away can lead to dehydration and kidney problems. Severe stomach pain, gallbladder symptoms, or symptoms that make it hard to keep food or fluid down deserve prompt clinician input rather than self-experimentation.

A good educational article should reduce guesswork, not encourage someone to manage red-flag symptoms alone. If symptoms are severe, escalating, or interfering with basic function, the next step is medical guidance.

Next step

Move from explanation into action with the related GLP-1 Simple resource.

Open the tracker →

Sources